How Real-World Regorafenib Dosing Correlates With Prior Sorafenib Treatment in HCC
Richard Finn, MD, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib in patients with unrespectable hepatocellular carcinoma.
Richard Finn, MD, a hematologic oncologist at the UCLA Jonsson Comprehensive Cancer Center, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib (Stivarga) in patients with unrespectable hepatocellular carcinoma (HCC).
According to Finn, all of the patients in the study were previously treated with sorafenib (Nexavar). Care providers either administered a full dose of regorafenib, or the dose of their choice. Some patients were administered 120 mg or as little as 80 mg of regorafenib daily. Dosing seemed to be based on the prior sorafenib dose, Finn notes.
Survival in the group was about 13 months. Adverse events were similar to those observed in the RESORCE study (NCT01774344). Additionally, according to Finn, the safety profiles was similar regardless of the dose. Dose de-escalation was also determined to be related to prior sorafenib.
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
